Differential induction of progestin-binding sites in uterine cell types by estrogen and antiestrogen.
Effects of antiestrogen on progestin binding in uterine cell types were determined and compared to those of estrogen. Effects on uterine morphology were also studied. Immature rats were treated with four daily sc injections of 100 micrograms hydroxytamoxifen [TAM(OH)], 5 micrograms estradiol (E2), or oil. On day 5 the rats were injected iv with 1 microgram of the synthetic progestin [3H]Org 2058, and 1 h later uteri were excised, weighed, and processed for thaw-mount autoradiography. Treatment with TAM(OH) or E2 resulted in uterine weight gain, which was greater in animals treated with E2. E2 treatment resulted in cellular hypertrophy in all tissue compartments, especially in the luminal epithelium and myometrium, but TAM(OH) treatment resulted in hypertrophy of only the luminal epithelium. Treatment with TAM(OH) or E2 changed the pattern and intensity of nuclear binding of [3H]Org 2058 from that in oil-treated controls. E2 increased progestin binding in stroma and myometrium and decreased it in luminal epithelium. TAM(OH), similarly, decreased progestin binding in the luminal epithelium and increased it, albeit less than E2, in the myometrium, but left it unchanged in the stroma. The results indicate that E2 and TAM(OH) differentially effect progestin binding among the uterine tissue compartments.
Ennis
B W
BW
Department of Cell Biology and Anatomy, University of North Carolina, Chapel Hill 27514.
Stumpf
W E
WE
D000818:Animals; D001345:Autoradiography; D004848:Epithelium / Q000378:metabolism; D004958:Estradiol / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D009215:Myometrium / Q000378:metabolism; D011282:Pregnenediones / Q000378:metabolism; D045167:Progesterone Congeners / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011980:Receptors, Progesterone / Q000096:biosynthesis* / Q000187:drug effects; D012016:Reference Values; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology; D014316:Tritium; D014599:Uterus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*
D004965:Estrogen Antagonists; D011282:Pregnenediones; D045167:Progesterone Congeners; D011980:Receptors, Progesterone; D013629:Tamoxifen; D014316:Tritium; C016601:afimoxifene; C020175:16 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione; D004958:Estradiol